Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Unknown

Phase 1

Conditions

Breast Cancer

Treatments

Drug: 68Ga-NOTA-BBN-RGD

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT02749019

ZIAEB000073 (U.S. NIH Grant/Contract)

PUMCHNM012

Details and patient eligibility

About

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-BBN-RGD in breast cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN-RGD will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Full description

Gastrin-releasing peptide receptor (GRPR) is a member of the G protein-coupled receptor family of bombesin receptors, which is over-expressed in various types of cancer cells, including prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, glioma, lung cancer, ovarian cancers, endometrial cancers, renal cell cancer and gastrointestinal stromal tumors. BBN(7-14), with the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of molecular probes for the imaging of GRPR. On the other hand, the RGD moiety binds with integrin αvβ3 receptor, also plays an important role in the regulation of tumor growth, angiogenesis, local invasiveness, and metastatic potential in human breast cancer. To target both receptors, a heterodimeric peptide BBN-RGD was synthesized from bombesin(7-14) and c(RGDyK) through a glutamate linker and then labeled with 68Ga. An open-label whole-body PET/ CT study was designed to investigate the safety and dosimetry of 68Ga-NOTA-BBN-RGD and diagnostic performance of 68Ga-NOTA-BBN-RGD PET/CT in breast cancer patients.

Enrollment

40 estimated patients

Sex

Female

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Neoplasm identified by X-ray, ultrasound or MRI as breast cancer
To provide basic information and sign the written informed consent.

Exclusion criteria

Consisted of conditions of mental illness;
Severe liver or kidney disease with serum creatinine > 3.0 mg/dl (270 μΜ) or any hepatic enzyme level 5 times or more than normal upper limit;
Severe allergy or hypersensitivity to IV radiographic contrast
Claustrophobia to accept the PET/CT scanning
Pregnancy or breast feeding